Theravance Biopharma (TBPH) Change in Acquisitions & Divestments (2013 - 2026)

Theravance Biopharma (TBPH) has 14 years of Change in Acquisitions & Divestments data on file, last reported at $96.0 million in Q1 2026.

• Change in Acquisitions & Divestments for Q1 2026 came in at $96.0 million, up 194.48% year-over-year; the trailing twelve-month figure through Mar 2026 was $206.4 million (up 60.74% YoY), and the FY2025 annual result was $143.0 million, up 2.26% from the prior year.
• Change in Acquisitions & Divestments advanced to $96.0 million in Q1 2026 per TBPH's latest filing, from $65.5 million in the prior quarter.
• Over five years, Change in Acquisitions & Divestments peaked at $96.0 million in Q1 2026 and troughed at $17.0 million in Q3 2022.
• A 5-year average of $40.5 million and a median of $40.1 million in 2024 frame the typical range for Change in Acquisitions & Divestments.
• The sharpest annual moves came in 2022 and 2026: Change in Acquisitions & Divestments tumbled 58.01% in 2022, then soared 194.48% in 2026.
• A 5-year view of Change in Acquisitions & Divestments shows it stood at $49.3 million in 2022, then decreased by 15.06% to $41.9 million in 2023, then decreased by 4.36% to $40.1 million in 2024, then jumped by 63.6% to $65.5 million in 2025, then soared by 46.51% to $96.0 million in 2026.
• Business Quant data shows TBPH's Change in Acquisitions & Divestments at $96.0 million in Q1 2026, $65.5 million in Q4 2025, and $24.5 million in Q3 2025.